EUBREAST-03: Comparison of different surgical staging procedures after neoadjuvant treatment in BC patients

Prof Hans-Christian Kolberg from Marienhospital Bottrop in Germany is presenting EUBREAST-03, part of the AXSANA trial. This trial constitutes a consortium of breast cancer centres aimed at assessing the surgical modalities for axillary staging (including sentinel lymph node biopsy, targeted axillary dissection, and axillary dissection) in patients presenting with clinically positive lymph nodes following neoadjuvant treatment. Presently, the trial encompasses 5,000 patients from 282 breast cancer centres across 24 countries, undergoing a 5-year follow-up period, with iDFS established as the primary endpoint.

Reference:

Kolberg HC, Magnetic seeds used for the detection of target lymph nodes after neoadjuvant therapy for early breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial. SABCS 2023, #PO1-23-02